Yarui Ma

458 total citations
10 papers, 278 citations indexed

About

Yarui Ma is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Yarui Ma has authored 10 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Yarui Ma's work include RNA modifications and cancer (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Advanced Breast Cancer Therapies (2 papers). Yarui Ma is often cited by papers focused on RNA modifications and cancer (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Advanced Breast Cancer Therapies (2 papers). Yarui Ma collaborates with scholars based in China and United States. Yarui Ma's co-authors include Xiaobing Wang, Qing Zhu, Xiaolei Guo, Changzhu Duan, Zeyu Zhang, Yuchen Jiao, Junbo Liang, Yi‐Xin Zeng, Mei Liu and Jianqiang Cai and has published in prestigious journals such as Advanced Science, Signal Transduction and Targeted Therapy and Frontiers in Pharmacology.

In The Last Decade

Yarui Ma

9 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yarui Ma China	6	177	104	96	49	30	10	278
Zhou Yang China	7	214 1.2×	113 1.1×	174 1.8×	47 1.0×	20 0.7×	12	344
Shupeng Liu China	11	251 1.4×	85 0.8×	145 1.5×	45 0.9×	46 1.5×	27	382
Shuye Lin China	11	162 0.9×	46 0.4×	71 0.7×	51 1.0×	47 1.6×	18	270
Changyu Chen China	12	254 1.4×	64 0.6×	207 2.2×	45 0.9×	32 1.1×	40	427
Jin Sil Chung South Korea	8	188 1.1×	53 0.5×	85 0.9×	58 1.2×	27 0.9×	8	311
Mengqi Liu China	5	164 0.9×	133 1.3×	134 1.4×	51 1.0×	28 0.9×	9	276
Claire Conche United States	6	167 0.9×	115 1.1×	93 1.0×	96 2.0×	126 4.2×	9	360
Guifang Yu China	11	241 1.4×	38 0.4×	169 1.8×	57 1.2×	26 0.9×	19	369
Ce Luo China	3	149 0.8×	27 0.3×	96 1.0×	52 1.1×	56 1.9×	7	290
Klaus-Peter Gilbertz Germany	9	148 0.8×	50 0.5×	59 0.6×	92 1.9×	25 0.8×	14	344

Countries citing papers authored by Yarui Ma

Since Specialization

Citations

This map shows the geographic impact of Yarui Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yarui Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yarui Ma more than expected).

Fields of papers citing papers by Yarui Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yarui Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yarui Ma. The network helps show where Yarui Ma may publish in the future.

Co-authorship network of co-authors of Yarui Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Yarui Ma. A scholar is included among the top collaborators of Yarui Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yarui Ma. Yarui Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Zhang, Huan, Yarui Ma, Simiao Wang, et al.. (2025). In Situ Programming of the Tumor Microenvironment to Alleviate Immunosuppression for Pancreatic Cancer Immunotherapy. Advanced Science. 12(34). e04008–e04008.

2.

Lin, Weihao, Qi Zhang, Yarui Ma, et al.. (2024). MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis. Molecular Medicine. 30(1). 199–199. 4 indexed citations

3.

Ma, Yarui, et al.. (2023). Minimal residual disease in solid tumors: an overview. Frontiers of Medicine. 17(4). 649–674. 4 indexed citations

4.

Ma, Yarui, Yong Fu, Yutong Li, et al.. (2022). GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma. Frontiers of Medicine. 17(1). 119–131. 9 indexed citations

5.

Ma, Yarui, Junbo Liang, Mo Li, et al.. (2021). AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduction and Targeted Therapy. 6(1). 299–299. 88 indexed citations

6.

Zhang, Zeyu, Yarui Ma, Xiaolei Guo, et al.. (2021). FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma. Frontiers in Pharmacology. 12. 749134–749134. 126 indexed citations

7.

Ma, Yarui, Qing Zhu, Tongzheng Liu, et al.. (2021). An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment. Frontiers in Pharmacology. 12. 707930–707930. 21 indexed citations

8.

Ma, Yarui, Siyuan He, Aiai Gao, et al.. (2020). Methylation silencing of TGF-β receptor type II is involved in malignant transformation of esophageal squamous cell carcinoma. Clinical Epigenetics. 12(1). 25–25. 16 indexed citations

9.

Ma, Yarui, Junbo Liang, Yifei Li, et al.. (2020). A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo. Signal Transduction and Targeted Therapy. 5(1). 152–152. 9 indexed citations

10.

Ma, Yarui, Qing Zhu, Junbo Liang, et al.. (2020). A CRISPR Knockout Negative Screen Reveals a Synergy between CDKs Inhibitor and Metformin in the Treatment of Human Cancer <i>in vitro</i> and <i>in vivo</i>. SSRN Electronic Journal. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact